Mouse Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein

Product specifications

Proteins and Peptides

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

E. coli

Mouse

Unconjugated

Molecular Weight: Calculated MW: 87.3 kDa
Concentration: Prior to lyophilization: 200 µg/ml
Sequence Fragment: Ser156-Gln694
Tag: N-terminal His tag and GST tag

Recombinant

> 90%

10 µg

50 µg

100 µg

200 µg

500 µg

Lyophilized To keep the original salt concentration, we recommend reconstituting to the original concentration prior to lyophilization (see Concentration) in ddH2O. If a lower concentration is required, dilute in PBS, pH 7.4. If a higher concentration is required, the product can be reconstituted directly in PBS, pH 7.4, though please note that this will change the overall salt concentration. The stock concentration should be between 0.1-1.0 mg/ml. Do not vortex.

WB, SDS-PAGE

Prior to lyophilization: PBS, pH 7.4, containing 0.01% Sarcosyl, 1 mM DTT, 5% Trehalose and Proclin-300.

Shipped within 5-7 working days.

Store at 2-8 °C for up to one month. Store at -80 °C for up to one year. Avoid repeated freeze/thaw cycles.

No

FH3,PC9,FHCL3,NARC1,LDLCQ1,NARC-1,HCHOLA3

Protein PCSK9

RUO

This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

PCSK9 is a serine protease that plays a central role in cholesterol metabolism by regulating the levels of low-density lipoprotein receptors (LDLR) on the cell surface. PCSK9 binds to LDL receptors, promoting their internalization and subsequent degradation in lysosomes, which reduces the uptake of LDL cholesterol (LDL-C) from the bloodstream. Elevated PCSK9 activity leads to hypercholesterolemia and increases the risk of cardiovascular disease due to excessive circulating LDL-C levels. In contrast, loss-of-function mutations in PCSK9 result in reduced LDL receptor degradation, leading to low plasma cholesterol levels and decreased cardiovascular risk. PCSK9 inhibitors, such as monoclonal antibodies (e.g., alirocumab and evolocumab), are highly effective therapies for hypercholesterolemia and cardiovascular disease, as they block PCSK9's activity, preserving LDL receptors on cell surfaces to enhance cholesterol clearance. Beyond lipid metabolism, PCSK9 has been implicated in inflammation, immune regulation, and other pathological processes, making it a versatile target for therapeutic intervention. Its crucial role in cholesterol homeostasis underscores its significance in cardiovascular health and disease management.

Related Products

Guinea pig PCSK9(Proprotein Convertase Subtilisin/Kexin Type 9) ELISA Kit

Ver Producto

Human PCSK9(Proprotein convertase subtilisin/kexin type 9) ELISA Kit

Ver Producto

Mouse PCSK9(Proprotein convertase subtilisin/kexin type 9) ELISA Kit

Ver Producto